MAZE
Maze TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
MAZE Profile
Maze Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing genetics-based precision therapeutics
171 Oyster Point Blvd., Suite 300, South San Francisco, California 94080
--
Maze Therapeutics, Inc. was incorporated under the laws of the State of Delaware on August 29, 2017. The company is a clinical-stage biopharmaceutical company that leverages the power of human genetics to develop novel small molecule precision medicines for patients with renal, cardiovascular and related metabolic or CVRM diseases, including obesity. The company is advancing a pipeline using their Compass platform, which allows them to identify and characterize genetic variants in diseases, and then link these variants to biological pathways that drive disease in specific patient populations through a process the company calls mutation functionalization. Their compass platform is built to inform all stages of the drug discovery and development process through clinical trial design. The company is currently advancing two wholly-owned lead projects, MZE 829 and MZE 782, each representing a new precision medicine-based approach to chronic kidney disease (CKD).
